Similarly, while the proportion of total tumor-infiltrating macrophages was comparable between treatment groups, Tras IgE-treated mice showed lower levels of alternatively activated CD163+CD206+, but comparable levels of classically-activated CD80+CD86+ macrophages, supporting a shift away from immunosuppression. This evidence concerns the gene CD163 and neoplasm.